counter customizable free hit

America's Seniors at www.TodaysSeniorsNetwork.com
 

 

 

 

 

 

Have Diabetes?  Your supplies may be covered!

Potential risk factor identified for Parkinson's
 
 


Home
Up
Beneficial Enzyme
Brain Disorder Link
Brain Stimulation
Calcium-Induced Death
Cell-based Therapy
Cholesterol Link
Clue to Parkinson's
Compulsive Behavior
Delaying Dementia
Deep Brain Stimulation
Depression Cause Link
Energy Supplment Test
Exercise Preventive
Falls Prevention
Fighting Tremors
Fox Commitment
Gambling Site Problem
Gambling, Meds Link
Gene Therapy Safe, Works
Green Tea Parkinson's Benefit
Home & Parkinson's
India Trials
Light Therapy Helps
Michael Fox Grant
Melanoma Link
Music to the Ears
New Therapies
OTC Drugs Effective
Oxygen Link
Parkinson's Brain Link
Parkinson's Cause
Parkinson's Causes
Parkinson's DVD
Parkinson's Impact
Parkinson's,Iron Link
Parkinson's Links
Parkinson's, D Link
Parkinsonism Link
Parkinson's Protein
Parkinson's Puzzle
Parkinson Risk Factos
Patients Fight Disease
Playing Havoc
Possible Cure
Post-Stay Depression
Reducing Tremors
Risk Takers
Serotonin Impact
Sleep Disorder Clue
Slowing Parkinson's
Slowing Progression
Therapeutic Clonining in Mice
Thinking & Falls
Tracing Deadly Path
Trial Procedure Works
Trigger Discovered
Veto Reaction

Home
45 Million Uninsured
Abdominal Screenings
ALS Gene Link
ALS Gene Link
Alzheimer's News
Addiction
Allergy Season
Deaf Seniors
Arthritis,Bones
Blacks & Obesity
Blood Pressure News
Brushing Dentures
Cancer Headlines
Chronic Disease
Craig Screenings
Chronic Pain, Disease
Dental Health
Reliable Ovarian Test
diabetes_news
Diet
Disabilities Examined
Exercise News
Falls, Serum Link
Faith & Health
Fibromyalgia
Flu Season
Foot Care
Foot Care Myths
Get Involved
Hearing
Heart & Stroke News
Hormone Therapy News
HRT, Incontinence
How's Your Thyroid
Incontinence Sufferers
Hip Replacement Advances
HIV, Aging Population
Incontinence Relief
Kiss, Don't Shake Hands
Lack of Action
Lung Transplants
Kidney News, Information
Liver Health News
Marrow Transplants
Medical Causes Falls
Mental Health
Million with Shingles
New Alliance
Obesity Problems
Overactive Bladder
Parkinson's News
Post-Op Delerium
Psoriasis Disease Links
Problems Accumulate
Scar-Free Healing
Seeking a Cure
Seniors Health Tips
Seniors, Shingles
Spinal Injuries
Successful Therapy
Surgeon's Age
Surgery Information
Testosterone Test
Thyroid Screening
Vision and Eye Care
vitamin_use.htm
Skin and Seasons
Throat Problems
Thyroid Surgery Danger
Urinary Tract, Falls
Voice Tips
When to Call Doctor
Worst Pain?
Varicose Vein Therapy
Vertigo Treatment
Thyroid Problems
3-D Mapping

 

 

 


Google
 

 

Web TodaysSeniorsNetwork.com
 

New Service for TodaysSeniorsNetwork.com readers...roll mouse over, click on highlighted links in stories to review items from Amazon

AddThis Feed Button   Now, keep up to date with daily feeds of newly posted stories about America's Seniors...click on the box to the left

Potential risk factor identified for Parkinson's

 

Newswise — A new study demonstrates that high levels of MAO-B, an enzyme that regulates nerve activity in the brain, cause Parkinson’s-like symptoms in mice genetically engineered to overexpress the protein.

 Furthermore, drugs currently used as an adjunct therapy for Parkinson’s in humans prevented the development of Parkinson’s symptoms in these same animals.

The findings, by scientists at the Buck Institute for Age Research, raise the possibility that humans could be tested to see if they have a risk factor for the progressive, incurable neurodegenerative disorder that affects 1.5 million Americans and receive preventive treatment.

The study appears in the February 20 issue of the open-access, online Journal, PLoS One.

 

Levels of measurable MAO-B vary 50-fold in humans and tend to increase with age. Several studies have suggested that increases in MAO-B contribute to the neurodegeneration associated with PD, but direct proof of a causative role for the enzyme has been lacking.

The drug deprenyl, which inhibits MAO-B, is a longstanding therapy for Parkinson’s used together with drugs that boost the level of dopamine, an important neurotransmitter that is preferentially depleted in the disease.

Clinical studies that suggest that deprenyl treatment alone does not impact mortality associated with Parkinson’s have cast doubt on the role of MAO-B in the disease itself. Buck faculty member Julie Andersen, PhD, who led the study says that may not be the case.

“Those studies were targeted to patients who already had symptoms of Parkinson’s -- by the time Parkinson’s is symptomatically detectable, dopamine loss is usually at least 60%,” said Andersen.

“Therefore the lack of effectiveness of MAO-B inhibition in these patients does not negate a role for MAO-B increase in disease development.”

Andersen added, “We have demonstrated that elevations in MAO-B result in selective loss of neurons associated with Parkinson’s in a mouse model and that the severity of this loss is age-dependent.”

Tests to measure levels of MAO-B are not currently available to the general public, although enzyme levels are tracked in clinical trials. Andersen says MAO-B testing could be akin to current practices involving cholesterol, which is measured and monitored as a risk factor for cardiovascular disease.

“However, it is important to note that Parkinson’s is a multi-factor disease,” said Andersen. “The fact that someone has high levels of MAO-B does not necessarily mean they are fated to develop Parkinson’s.”

Andersen said results of the study point to the need for an early diagnostic test for Parkinson’s.

"Currently, by the time people are diagnosed with the disease they have already lost 60% of the neurotransmitter levels implicated in Parkinson’s; treatment with a drug like deprenyl would likely be most effective if taken before symptoms appear in order to halt disease progression."

The novel transgenic mouse line created for this study provides a new model for exploring molecular pathways involved in the initiation or early progression of several key features associated with Parkinson’s pathology including dopaminergic midbrain cell loss. The mouse line also allows for additional therapeutic drug testing.

Joining Andersen in the study were Jyothi K. Mallajosyula, Deepinder Kaur, Shankar J. Chinta, Subramanian Rajagopalan, Anand Rane, and David G. Nicholls of the Buck Institute, along with Dino DiMonte of the Parkinson’s Institute and Heather Macarthur of the Saint Louis University School of Medicine. The work was funded by the National Institutes of Health (R01 NS40057-04) and the National Parkinson’s Foundation.

The Buck Institute is an independent non-profit organization dedicated to extending the healthspan, the healthy years of each individual’s life.

The National Institute of Aging designated the Buck a Nathan Shock Center of Excellence in the Biology of Aging, one of just five centers in the country.

Buck Institute scientists work in an innovative, interdisciplinary setting to understand the mechanisms of aging and to discover new ways of detecting, preventing and treating age-related diseases such as Alzheimer’s and Parkinson’s disease, cancer, stroke, and arthritis.

Collaborative research at the Institute is supported by genomics, proteomics and bioinformatics technology. For more information: www.buckinstitute.org.

 

 

 

 

...
...
...

 

 

 



Home
Up
About Us
America's Seniors WebMall
Aging News
California Report
Caregiving
Community/Workplace
Fitness,Health
Grandparents
Health Care Policy
Hispanic Seniors
Medicare News
Contents/Sitemap
Prescription Drugs
Pharma Suits
Restaurant Reviews
Rural Seniors
Safety & Security
Seniors Commentary
Seniors' Entertainment
Seniors Headlines
Seniors Finances
Seniors' Issues
Seniors Relationships
Seniors Rights
Social Security News
The Virtual Family
Travel News
TSN Radio on Web
Veterans' Tribute
White House Cards
Privacy Policy
Consumer Alert
Pull Plug Heat Costs

 

 

 

 

 To Contact Us, Click here
Copyright (C) 1999-2009 TodaysSeniorsNetwork.com